Kaival Brands Innovations Group Inc. (KAVL) to Develop Smoking Cessation Products Using Purified, Synthetic Nicotine [Video Edition]

Approximately 1,300 people die every day as a result of smoking, and more than 16 million Americans are living with a disease caused by smoking. These alarming numbers aren’t going unnoticed, and companies with expertise in the space are seizing the opportunity to provide solutions designed to help smokers kick the habit. One of those companies, Kaival Brands Innovations Group Inc. (OTCQB: KAVL), has just acquired a patent covering the creation of all synthetic nicotine smoking cessation and synthetic nicotine addiction therapy products; the company is also creating a subsidiary that will own the patent and develop all related products. The maker of Nicorette(R), GlaxoSmithKline PLC (NYSE: GSK) creates innovative nicotine replacement therapies and smoking cessation products, including the Nicorette(R) product line. Perrigo Company PLC (NYSE: PRGO) offers a healthy lifestyle product portfolio that includes a full range of oral nicotine products designed to help smokers kick the habit or cut down on tobacco use. Altria Group (NYSE: MO) has created QuitAssist(R), an online resource to help smokers who are trying to quit be more successful. And Reynolds American Inc., owned by British American Tobacco Industries (NYSE: BTI), has a Tobacco Harm Reduction (“THR”) campaign designed to reduce the risks faced by adult tobacco smokers by providing them with accurate information tobacco and smoking.